NerPharMa Appoints Claudio Salvagnini as Deputy CEO
November 22, 2023

Nerviano_2023-09-01_NerPharMa Srl (NerPharMa), a leading Contract Development and Manufacturing Organization (CDMO), is pleased to announce the appointment of Claudio Salvagnini as the Deputy CEO, effective immediately.

Since Claudio joined the leadership team earlier this year, he has been a driving force in the recent turning around NerPharMa. As the Deputy CEO, he will play a critical role in shaping the company’s strategic direction and ensuring operational efficiency.

In this enhanced capacity, Claudio will also take on a more focused leadership role, dedicated to refining and optimizing the company’s business operations, supply chain initiatives, project management strategies and developing client portfolio, leveraging his extensive experience and proven leadership. Also, he will spearhead initiatives aimed at streamlining processes, enhancing productivity, and fortifying relationships with our existing and new clients and long-term partners.

“Claudio has been a catalyst for innovation and progress within our organization,” stated Hugues Dolgos, PharmaD, at NerPharMa. “The elevation of his role underscores our commitment to leverage his exceptional network and knowledge in the CDMO operations and customer needs, elevating and fortifying our position as a leading niche CDMO and CMO partner in the biotech and pharma industry.”

Claudio expressed his enthusiasm for the new role, stating, “I am very excited to take on this new role in NerPharMa. I am committed to fostering operational excellence, driving innovation, and ensuring full satisfaction of our clients by further strengthening our support level, with customized supply chain and project management solutions, aligning with the evolving needs of our partners. The unique selling proposition of NerPharMa, offering fully integrated drug substance, drug product and final packaging of highly potent drugs from our Bio-Park in Nerviano (Milan, IT), provides already seamless support to global pharma companies from late discovery, through clinical development to commercialization stage across the whole product lifecycle. We will continue in building on decades of experiences on the field by focused investment in new technologies and capabilities to meet and exceed our customers’ expectations. I am honored and proud to be part of this journey.”

The company remains dedicated to advancing pharmaceutical and biotech manufacturing, and Claudio’s elevated role underscores the company’s commitment to meeting the evolving needs of our clients, nurturing and empowering its internal talent to lead critical functions.

Link PR: 20231121-NerpharMa-Deputy CEO-Final

from NMSGroup

 

Welcome and Check out our new motion picture!

WATCH OUR VIDEO